A newly approved drug for Prader Willi syndrome, a rare genetic disorder causing extreme hunger and obesity, is under scrutiny after experts raised concerns about potential safety issues, including patient deaths. The drug, developed by Neurocrine Biosciences, received FDA approval earlier this year. While the exact cause of the deaths remains unclear, regulators and clinicians are closely monitoring the situation to determine whether the medication may be contributing to adverse outcomes in vulnerable patients.
Neurocrine Biosciences’ newly approved drug for Prader Willi syndrome, a rare genetic disorder characterized by an insatiable appetite and metabolic complications, is facing scrutiny after reports of patient deaths potentially linked to its use. The drug, which received FDA approval in early 2024, is designed to address hyperphagia, the extreme, life threatening hunger associated with the condition.
While the exact relationship between the drug and the reported fatalities remains unclear, experts and regulators are investigating whether the medication may have contributed to adverse events in some patients. Prader Willi syndrome affects approximately 1 in 10,000 to 30,000 people worldwide, and patients often struggle with severe obesity, behavioral challenges, and metabolic disorders.
DISCUSSION (0)